Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug | Frank Vinluan | 09/01/20 | San Francisco |
Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline | Frank Vinluan | 06/04/20 | Boston |
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More | Ben Fidler | 07/26/19 | National |
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More | Alex Lash | 01/11/19 | National |
Bio Roundup: ASCO Abstracts, Migraine Drug Prices & “Blueprint” Fallout | Alex Lash | 05/18/18 | National |
Visterra, Braeburn Stumble After Solid ’17 Start for Bio IPOs | Ben Fidler | 02/10/17 | Boston |
Bio Roundup: Trump News, Anthem’s Stand, Diversity by 2056 & More | Ben Fidler | 01/27/17 | National |
Jounce Gets $102M As Biotech IPOs Gain Steam in ’17 | Ben Fidler | 01/27/17 | Boston |
First Trial Underway, Jounce Preps IPO To Fund Immuno-Oncology Work | Ben Fidler | 01/03/17 | Boston |
MIT’s Jacks Leans on Disney Family, Not VCs, to Hatch New Startup | Ben Fidler | 08/11/16 | Boston |
Biotech Roundup: Scangos’s Exit, Zafgen’s Shakeup, Jounce, Relypsa & More | Ben Fidler | 07/22/16 | National |
Oncorus Bags $57M, Touts Next-Gen Take on Cancer-Fighting Viruses | Ben Fidler | 07/19/16 | Boston |
With Celgene Deal, Jounce Lands $261M And a “Trusting Partner” | David Holley | 07/19/16 | Boston |
Atlas, Novartis Put $27M Into IFM to Battle Cancer, Autoimmune Diseases | Ben Fidler | 06/22/16 | Boston |
With New Execs, Sanofi Backing, ImmuneXcite Begins Clinical Push | Ben Fidler | 03/30/16 | Boston |
RaNA CEO Renaud Turns To A Former Backer To Lead $55M Series B | Ben Fidler | 07/23/15 | Boston |
Ex-AstraZeneca Exec to Lead Surface’s “Next-Gen” Immuno-Oncology Plan | Ben Fidler | 05/07/15 | Boston |
Adaptive Reels in Whopping $195M For Immuno-Sequencing Work | Alex Lash | 05/06/15 | Seattle |
With $46M Haul, MyoKardia Becomes Third Rock’s Latest IPO Prospect | Ben Fidler | 04/30/15 | San Francisco |
East Coast Biotech Roundup: Forum, Crossovers, Immuno-Oncology & More | Ben Fidler | 04/24/15 | Boston |
Crossovers Arm Jounce With $56M For “Next Step” Immuno-Oncology | Ben Fidler | 04/23/15 | Boston |
Jounce Therapeutics Secures $56,000,000 Series B Funding | VentureDeal | 04/23/15 | Boston |
East Coast Biotech Roundup: Acceleron, Seres, Sage, & More | Ben Fidler | 07/18/14 | Boston |
East Coast Biotech Roundup: Regeneron, Sarepta, Jounce, & More | Ben Fidler | 07/11/14 | Boston |
New Jounce CEO Aims to Place the Right Immuno-Oncology Bets | Ben Fidler | 07/11/14 | Boston |
Jounce Taps Merck Vet to Lead Cancer Drug Push | Ben Fidler | 07/10/14 | Boston |
East Coast Biotech Roundup: Gerngross, Akili, Intercept, & More | Ben Fidler | 01/10/14 | Boston |
Juno Therapeutics Grabs $120M to Coax Immune System to Fight Cancer | Luke Timmerman | 12/03/13 | Seattle |
Armo BioSciences Joins the Cancer Immunotherapy Party With $20M | Luke Timmerman | 11/25/13 | San Francisco |